Ginkgo biloba and acetazolamide for acute mountain sickness: exclusion of high risk, low status groups perpetuates discrimination and inequalities
- PMID: 15258082
- PMCID: PMC478272
- DOI: 10.1136/bmj.329.7458.171-b
Ginkgo biloba and acetazolamide for acute mountain sickness: exclusion of high risk, low status groups perpetuates discrimination and inequalities
Comment on
-
Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT).BMJ. 2004 Apr 3;328(7443):797. doi: 10.1136/bmj.38043.501690.7C. Epub 2004 Mar 11. BMJ. 2004. PMID: 15070635 Free PMC article. Clinical Trial.
References
-
- Gertsch JH, Basnyat B, Johnson EW, Onopa J, Holck PS. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial (PHAIT) BMJ 2004;328: 797-801. (3 April.) - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources